Last reviewed · How we verify
midazolam，fentanyl，rocuronium
This is a combination of three marketed anesthetic and neuromuscular agents: midazolam (benzodiazepine sedative), fentanyl (opioid analgesic), and rocuronium (neuromuscular blocking agent) used together for anesthesia induction and maintenance.
This is a combination of three marketed anesthetic and neuromuscular agents: midazolam (benzodiazepine sedative), fentanyl (opioid analgesic), and rocuronium (neuromuscular blocking agent) used together for anesthesia induction and maintenance. Used for Induction and maintenance of general anesthesia, Sedation and analgesia during mechanical ventilation in intensive care settings.
At a glance
| Generic name | midazolam，fentanyl，rocuronium |
|---|---|
| Also known as | Liyuexi，Fentanyl Citrate Injection，Aikesong |
| Sponsor | Tang-Du Hospital |
| Drug class | Anesthetic combination (benzodiazepine + opioid + neuromuscular blocker) |
| Target | GABA-A receptor (midazolam); mu-opioid receptor (fentanyl); nicotinic acetylcholine receptor at neuromuscular junction (rocuronium) |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | FDA-approved |
Mechanism of action
Midazolam acts as a GABA-A receptor agonist to produce sedation and anxiolysis. Fentanyl is a mu-opioid receptor agonist that provides analgesia and enhances sedation. Rocuronium is a non-depolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the neuromuscular junction to produce skeletal muscle paralysis for intubation and mechanical ventilation.
Approved indications
- Induction and maintenance of general anesthesia
- Sedation and analgesia during mechanical ventilation in intensive care settings
Common side effects
- Respiratory depression
- Hypotension
- Bradycardia
- Prolonged neuromuscular blockade
- Postoperative nausea and vomiting
Key clinical trials
- Magnesium Sulfate Versus Other Anesthesia Drugs to Reduce Agitation After Adenotonsillectomy in Pediatric Patients (NA)
- The Effect of the Anticholinergic Burden Following Elective Coronary Artery Surgery (PHASE4)
- Intubation Conditions Achieved With Rapid Co-administration of Rocuronium and Propofol Versus Classical Induction (PHASE4)
- Assessment of Endotracheal Tube Temperature Effects in Children Undergoing Adenotonsillectomy (NA)
- SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke (PHASE4)
- Investigation of the Optimum PEEP Mechanical Power Relationship
- Standardised Drug Provocation Testing in Perioperative Hypersensitivity (NA)
- Impact of Anesthesia Maintenance Methods on 5-year Survival After Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- midazolam，fentanyl，rocuronium CI brief — competitive landscape report
- midazolam，fentanyl，rocuronium updates RSS · CI watch RSS
- Tang-Du Hospital portfolio CI